ENDO PHARMACEUTICALS WKN: A1XE6M ISIN: IE00BJ3V9050 Kürzel: EO7 Forum: Aktien Thema: Hauptdiskussion

Sorgen oder Entspannung?

Bewater was sagst du dazu? Ehrliche Meinung

Panik wird eher kurz mal nen Pump

Also keine Panik.

Genauso verstehe ich das auch.

https://stocktwits.com/Alexhere/message/479028939

sieht so aus

Also so gesehen gibt es ein Kompromiss und das Unternehmen geht nicht Insolvenz Die Geschäfte laufen weiter und es werden Profite erzielt… verstehe ich es richtig?

es geht los ??? :D

es geht los :D ???

Wieso ist das Volumen heute so brutal

klingt positiv nach Umstrukturierung

The Company is filing with the Court a series of customary motions to maintain business-as-usual operations on all fronts and uphold its commitments to its stakeholders, including team members, customers, suppliers, and business partners, during the process. Approval of these routine "first day" motions, which the Company expects to receive in short order, will help facilitate a smooth transition into the process. 

Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN, Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebtedness, address remaining opioid and other litigation-related claims, and best position Endo for the future. This will allow Endo to advance its business transformation with a strengthened balance sheet to create compelling value for its stakeholders over the long term. Under the RSA, the debtholder group has committed to providing total purchase consideration of approximately $6 billion in the form of a credit bid, plus assumption of certain liabilities, for substantially all of the Company's assets. The transaction contemplates that the purchaser will: Offer employment to all of Endo's active team members; Establish voluntary trusts, to be funded with $550 million over 10 years, whereby future proceeds will be set aside for certain opioid claims; and Have net funded leverage in an amount no greater than 4.5x. This "stalking horse" bid will be subject to higher or otherwise better offers. To facilitate the sale process and provide an appropriate forum for bringing closure to opioid-related and other uncertainties without the need for continued costly, time-consuming litigation, Endo and certain of its subsidiaries initiated voluntary prearranged Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York ("Court"). Endo's India-based entities are not part of the Chapter 11 proceedings. The Company expects to file recognition proceedings in Canada, the United Kingdom, and Australia. "Today's announcement is a significant milestone as we advance our strategic priorities and business transformation so that Endo's value proposition can be realized," said Blaise Coleman, Endo's President and Chief Executive Officer. "By definitively addressing the more than $8 billion of debt that has burdened our balance sheet and establishing a pathway to closure with respect to the thousands of opioid-related and other lawsuits that the Company has been defending at an unsustainable cost, we will be able to move forward as a new Endo and reach our full potential." Mr. Coleman continued, "This process will enable us to continue our ongoing business transformation, including investing in our core areas of growth, as we work to execute a transaction to strengthen our balance sheet and secure a strong tomorrow. Our commitment to our mission, team members, customers, patients, and communities will not change, and we look forward to emerging from this process better positioned to continue helping everyone we serve live their best lives." The Company's secured creditors have consented to use of cash collateral to fund the Company's day-to-day business during the process. This significant cash on hand, coupled with positive cash flow from operations, will provide ample liquidity as the Company continues to deliver the life-enhancing products that its customers and their patients expect today and in the future. Notably, the Company and a consortium of state attorneys general have agreed on certain injunctive terms relating to the sale of Endo's opioid products, including with respect to promotion, funding/grants to third parties, and suspicious order monitoring, which will be presented to the Court for approval.

ich kann die Nachricht nicht sehen, bzw. nicht unter deinem Link A r n o l d i n h o

Guten Morgen. Ich habe das schnell überflogen. Ich konnte bezüglich der Aktionäre nichts rauslesen. Der Bericht ist meiner Meinung nach eher positiv. Dass man auf eine Einigung aus ist. Korrigiert mich bitte, wenn ich was wichtiges übersehen habe.